title: Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
abstract: We have recently reported on the outcome of autologous transplantation in the rare myelomas (IgD, IgE, IgM, and nonsecretory [NS]) but there is no real information on the outcome of these conditions after allogeneic transplantation. We used the European Group for Blood and Marrow Transplantation myeloma database to compare the outcomes after allogeneic transplantation of 1354 common myelomas (IgG, IgA, and light chain myeloma) with the outcome in 26 IgD myelomas and 52 NS myelomas. There was little difference between common and the IgD and NS myeloma patients with respect to prognostic factors although the IgD group had a higher beta 2 microglobulin at diagnosis, shorter time to transplantation, and more T cell depletion. IgD and NS patients had a significantly greater achievement of complete remission at conditioning but this did not translate into equivalent progression-free survival and overall survival for the IgD patients although the NS outcome was very similar to that of common myeloma. The PFS and OS of IgD, common, and NS myelomas appear similar after allogeneic transplantation, despite a tendency for higher early relapse rate in IgD myeloma. Allogeneic transplantation may, therefore, be an option to investigate in prospective observational studies.
authors.affiliation: Centre for Cancer Research and Cell Biology, Queens University, Belfast, United Kingdom. Electronic address: curlymorris_cliff@yahoo.com.
authors.forename: Curly
authors.initials: C
authors.lastname: Morris
authors.affiliation: Centro di Biostatistica e Bioinformatica, Università di Roma Tor Vergata, Rome, Italy.
authors.forename: Simona
authors.initials: S
authors.lastname: Iacobelli
authors.affiliation: Department of Medicine, Karolinska Institutet & Karolinska University Hospital, Huddinge, Stockholm, Sweden.
authors.forename: Gösta
authors.initials: G
authors.lastname: Gahrton
authors.affiliation: European Group for Blood and Marrow Transplantation Data Office, Leiden University Medical Centre, Leiden, The Netherlands.
authors.forename: Anja
authors.initials: A
authors.lastname: van Biezen
authors.affiliation: Haematology Department, Belfast City Hospital, Belfast, United Kingdom.
authors.forename: Mary
authors.initials: M
authors.lastname: Drake
authors.affiliation: Department of Haematology, Saint Antoine Hospital, Paris, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Garderet
authors.affiliation: Leukaemia Myeloma Units, Royal Marsden Hospital, London Surrey, United Kingdom.
authors.forename: Michael
authors.initials: M
authors.lastname: Potter
authors.affiliation: Department of Hematology, University Medical Center St, Radboud, Nijmegen, The Netherlands.
authors.forename: Anton V
authors.initials: AV
authors.lastname: Schattenberg
authors.affiliation: Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
authors.forename: Jan J
authors.initials: JJ
authors.lastname: Cornelissen
authors.affiliation: Service d'Hematologie, Centre Pierre et marie Curie, Alger, Algeria.
authors.forename: Rose-Marie
authors.initials: RM
authors.lastname: Hamladji
authors.affiliation: Sezione di Ematologia, University of Perugia, Perugia, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Martelli
authors.affiliation: Department of Hematology, University Medical Center, Utrecht, The Netherlands.
authors.forename: Eefke
authors.initials: E
authors.lastname: Petersen
authors.affiliation: Department of Hematology, Hospital Clinic, Barcelona, Spain.
authors.forename: Montserrat
authors.initials: M
authors.lastname: Rovira
authors.affiliation: Institute of Hematology, Bologna University S. Orsola, Bologna, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Bandini
authors.affiliation: Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
authors.forename: Nicolaus
authors.initials: N
authors.lastname: Kroger
authors.affiliation: Tumor Immunology, University Medical Center St, Radboud, Nijmegen, The Netherlands.
authors.forename: Theo
authors.initials: T
authors.lastname: de Witte
mesh_terms: D000328:Adult; D000368:Aged; D005060:Europe; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007072:Immunoglobulin D / Q000097:blood*; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000145:classification / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D019653:Myeloablative Agonists / Q000627:therapeutic use*; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D001613:beta 2-Microglobulin / Q000097:blood / Q000276:immunology
chemical_list: D007072:Immunoglobulin D; D019653:Myeloablative Agonists; D001613:beta 2-Microglobulin
keywords: Allogeneic transplantation; IgD; Myeloma; Nonsecretory myeloma